Nastech/Amylin’s Exenatide Nasal Spray Deal Could Be Shot In The Arm For Lilly
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly, which markets injectable exenatide, may inherit commercialization rights to the nasal spray formulation if Nastech/Amylin’s development proves successful.
You may also be interested in...
Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies
FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.
Neurocrine’s Bad Dream Continues: Indiplon FDA Approval Requires Three More Studies
FDA “approvable” letter for the insomnia agent is particularly stinging because Neurocrine was set to announce a new commercialization agreement with a leading pharma company.
Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs
Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.